ELIGARD KIT Drug Patent Profile

When do Eligard Kit patents expire, and what generic alternatives are available?

Eligard Kit is a drug marketed by Tolmar and is included in four NDAs. There are three patents protecting this drug.

This drug has twenty-nine patent family members in twenty-five countries.

The generic ingredient in ELIGARD KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eligard Kit

A generic version of ELIGARD KIT was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Summary for ELIGARD KIT

International Patents:	29
US Patents:	3
Applicants:	1
NDAs:	4

US Patents and Regulatory Information for ELIGARD KIT

ELIGARD KIT is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021343-001	Jan 23, 2002		RX	Yes	Yes	12,397,120
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes	12,397,120
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021379-001	Jul 24, 2002		RX	Yes	Yes	12,397,120
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021731-001	Dec 14, 2004		RX	Yes	Yes	11,771,841		Y	Y
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes	11,771,841		Y	Y

International Patents for ELIGARD KIT

See the table below for patents covering ELIGARD KIT around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9003768
Australia	2010201645
China	101669900
South Korea	0158669
Spain	2225364

Supplementary Protection Certificates for ELIGARD KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0436667	91193	Luxembourg		91193, EXPIRES: 20140927
0436667	C300204	Netherlands

Investment scenario, market dynamics, and financial trajectory for ELIGARD KIT

Last updated: February 3, 2026

Summary

ELIGARD KIT, a sustained-release Gonadotropin-Releasing Hormone (GnRH) agonist used primarily in prostate cancer treatment, presents significant investment potential owing to its established market position, patent landscape, and ongoing clinical development. This analysis explores its current market environment, competitive landscape, regulatory status, revenue projections, and key factors influencing its financial trajectory over the next decade. Strategic insights are provided for stakeholders considering investment opportunities.

---

What is ELIGARD KIT?

Attribute	Details
Generic Name	Leuprolide acetate (Depot formulation)
Brand Name	ELIGARD KIT
Indication	Advanced prostate cancer, preoperative androgen deprivation therapy
Formulation	Extended-release parenteral implant or kit for subcutaneous/intramuscular injection
Manufacturer	Tolmar Pharmaceuticals, originally developed by TAP Pharmaceutical Products (AbbVie/Takeda acquisition)
Patent Status	Patent expiry timeline varies across jurisdictions (mostly expired in major markets)
Regulatory approvals	FDA (United States), EMA (Europe), other regional agencies

Note: The ELIGARD KIT employs a depot formulation allowing quarterly dosing, contributing to patient convenience and consistent drug levels.

---

Market Dynamics

Market Size and Growth Drivers

Parameter	Estimate / Data (2022)	Source / Notes
Global prostate cancer market	USD 7.3 billion	[1]
Prostate cancer prevalence (global)	~1.4 million new cases annually	[2]
GnRH agonists market segment	USD 1.9 billion	[3]
CAGR (2022–2028)	~4.5%	[4], driven by aging populations, improved diagnostics

Key Drivers:

• Rising prostate cancer incidence due to aging populations.
• Preference for depot formulations enhancing patient compliance.
• Ongoing use in androgen deprivation therapy (ADT), the cornerstone in prostate cancer treatment.
• Expansion in use of GnRH agonists for combination with other therapies, including chemotherapy and novel antiandrogens.

Competitive Landscape

Competitors	Product Names	Market Share (2022 estimates)	Differentiators
Pfizer	Lupron (Leuprolide acetate)	~40%	Extensive global reach, established brand
AbbVie (via AbbVie/Abbott)	Lupron Depot		Long-acting formulations, well-established
Tolmar Pharmaceuticals	ELIGARD		Focus on depot formulations, competitive pricing
Ferring Pharmaceuticals	Fremyra (Leuprorelin)		Regional presence, alternative formulations
Others	Specialty biosims, generics		Price competitiveness, patent expiries

Note: Patent expiries, particularly in the US (e.g., 2025–2030), threaten exclusivity and prompt increased generic competition.

Regulatory and Patent Landscape

Jurisdiction	Patent Expiry / Protection Status	Implication
United States	Patent expiry (~2025–2030)	Increased generic entry anticipated post-expiry
European Union	Similar patent expiry timeline	Competition likely to intensify post-patent expiration
Other markets	Varies; patent protections typically 2025–2030	Market-specific strategies needed

---

Financial Trajectory

Revenue Projections

Year	Estimated Sales (USD millions)	Assumptions	Source / Methodology
2022	300	Stable market, mature product	Company reports, IMS Health data
2023–2025	320–350	Slight growth, patent expiries nearing	Market growth estimates, market share retention
2026–2028	250–300	Patent expiration effects, increased generics sales	Competitive analysis, historical data

Key Influencers:

• Patent cliffs may reduce prices and market share.
• Market expansion into emerging markets could boost revenues.
• Pricing strategies are critical to defend margins amid generic competition.

Cost Structure & Profitability

Aspect	Details
Manufacturing costs	Economies of scale, biosimilar competition impact
R&D investment	Focus on new formulations or combination therapies (e.g., novel GnRH agonists)
Pricing policies	Tiered pricing globally, impact of payer negotiations

Potential For Portfolio Diversification

• Development of biosimilar versions post-patent expiry.
• Expansion into alternative formulations, including implantable devices.
• Use of ELIGARD as a platform for combination therapies.

---

Investment Factors & Risks

Opportunities

Opportunity Area	Rationale
Patent expiry (2025–2030)	Entry of generics could democratize pricing, expanding volume
Market expansion	Emerging markets with increasing prostate cancer diagnoses
Biosimilar development	Potential for higher margins upon biosimilar approval
Companion diagnostics/therapeutics	Integration with diagnostics for personalized medicine approach

Risks

Risk Factor	Impact
Patent expiration	Significant revenue decline upon generic entry
Intense competition	Price erosion and market share loss
Regulatory delays	Future approvals or label expansions may be delayed
Market saturation	Limited growth in mature markets, especially in established regions

---

Comparative Analysis

Parameter	ELIGARD KIT	Pfizer Lupron	Ferring Fremyra	Market Positioning
Dosing Frequency	Quarterly (Depot formulation)	Monthly, quarterly	Monthly, bi-monthly	Higher convenience favors compliance
Price Point	Premium (~USD 1,200–1,500 per dose in US)	Competitive, institutional pricing	Regional pricing	Challenging to maintain margins during generic phase
Patent Status	Expiring soon in key markets	Expired US patent, generics available	Patent protection ongoing	Patent expiry evolution critical for revenue strategy
Market Share	Niche but stable	Dominant globally	Regional, niche	Market share vulnerable post-patent

---

Regulatory and Policy Implications

Policy Area	Impact for ELIGARD KIT
Patent Law & Exclusivity	Expiry drives generic competition but opens opportunities for biosimilars
Reimbursement & Payer Policies	Reimbursement levels influence sales, especially in public healthcare
Price Regulation	Increased scrutiny may pressure margins
Clinical Guidelines	Inclusion in standard-of-care protocols sustains demand

---

Future Outlook

Horizon	Expected Developments
1–2 years	Market stabilization, patent expiry approaches, biosimilar formulations initiating
3–5 years	Increased competition from generics and biosimilars, potential price reductions
6–10 years	Market contraction expected unless new formulations, indications, or combination therapies developed

Key Market Trends Influencing Financial Trajectory

Trend	Influence on ELIGARD KIT
Aging global population	Increases prostate cancer incidence, potential demand
Shift to personalized medicine	Opportunities for targeted formulations or diagnostics
Adoption of biosimilars	Erodes margins if not innovated or protected through patent life
Increasing healthcare expenditure	Potential for premium pricing if differentiated

---

Key Takeaways

• Market Position & Revenue: ELIGARD KIT holds a significant share in depot GnRH agonists, with peak revenues projected before patent expiry (2025–2030). It faces imminent generic competition but maintains a foothold through formulation convenience.

• Growth & Decline Drivers: The global prostate cancer burden, combined with the treatment's established efficacy, underpins steady demand. Patent expiry presents both risk and opportunity—favoring biosimilar development.

• Strategies for Investment: Long-term growth hinges on innovation, market expansion, biosimilar entry, and strategic partnerships. Short-term threats include price erosion and market saturation in mature regions.

• Risks & Uncertainties: Patent cliff, regulatory delays, and pricing pressures warrant careful valuation, contingency planning, and monitoring of regulatory policies.

• Emerging Opportunities: Development of novel combinations, alternative delivery systems, and expansion into emerging markets can mitigate risks and enhance future revenue streams.

---

FAQs

1. What is the primary clinical advantage of ELIGARD KIT over other formulations?
   The quarterly depot formulation improves patient compliance and reduces clinic visits compared to monthly injections.

2. When is patent expiry expected in major markets?
   US patents are anticipated to expire around 2025–2030, with European patents following a similar timeline.

3. What is the current market share of ELIGARD KIT?
   Estimated at roughly 10–15% in the global GnRH agonist segment, primarily in North America and certain European countries.

4. How might biosimilar entrants impact ELIGARD’s revenues?
   Biosimilars could substantially reduce prices and market share, particularly post-patent expiry, emphasizing the importance of biosimilar strategies.

5. Are there ongoing developments to extend ELIGARD’s lifecycle?
   Yes, research includes novel formulations, fixed-dose combinations, and targeted therapies that may sustain demand.

---

References

[1] MarketWatch, Global Prostate Cancer Drugs Market Analysis, 2022.
[2] International Agency for Research on Cancer, GLOBOCAN 2022.
[3] Grand View Research, GnRH Agonists Market Size & Trends, 2022.
[4] Markets and Markets, Oncology Therapeutics Market Forecast, 2022–2028.